Aperion Biologics
Anthony G. Viscogliosi, CEO

Aperion Biologics Corporation, a medical device company, develops animal-based tissue technologies as alternatives to human-based grafts in the United States and internationally. It offers Z-Process, a process that immunochemically modifies animal tissue, and humanizes and sterilizes tissues for orthopedic ligaments, bone, and meniscus; valves and vessels; soft tissue grafts for augmentation and repair; and plastic, dermatologic, and general surgical specialties. The company’s Z-Process is also used for tendon, ligament, articular cartilage, and fibrocartilage connective tissue grafts; heart valve and pericardium cardiovascular tissues; and calcified and de-calcified bones, such as granular bone matrix, cortical and cancellous structural bone for struts, cages, and machined implants. In addition, its Z-Process deactivates alpha-gal and non-gal antigens on the xenograft tissue to prevent rejection.. Aperion Biologics Corporation was founded in 1996 and is based in San Antonio, Texas.